Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Melanoma 34Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Ovarian Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 4Hematologic Neoplasms 4Solid Tumors 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Solid Tumor 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Histologic Type 2Leukemia, Myelomonocytic, Chronic 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × cobimetinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡